PerkinElmer completed its acquisition of Caliper Life Sciences, a Hopkinton, Mass.-based imaging and detection company, for approximately $600 million in cash.
Waltham, Mass.-based PerkinElmer announced the deal in September.
“The integration of Caliper into our organization will further strengthen PerkinElmer's position in personalized medicine,” said Robert Friel, PerkinElmer's chairman and CEO, in a news release. “The acquisition will enhance our ability to provide customers with the complementary technologies, services and knowledge they need to drive innovation from in vivo to in vitro imaging, and provide expanded offerings across our biomedical, diagnostics, environmental and food safety end-markets.”
Kevin Hrusovsky, CEO of Caliper Life Sciences, has been named president of life sciences and technology at PerkinElmer, the $500 million business unit that houses the company's existing research business and Caliper Life Sciences operations, according to a PerkinElmer spokeswoman.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.